XML 87 R77.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Oct. 02, 2022 | Oct. 03, 2021 | Oct. 02, 2022 | Oct. 03, 2021
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1] | $ 22,638 | $ 24,035 | $ 76,040 | $ 57,450
Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1],[2] | 22,319 | 23,513 | 75,066 | 56,101
PC1 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 319 | 521 | 974 | 1,348
Total Alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,689 | 2,068 | 6,320 | 5,718
Primary Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 15,846 | 16,680 | 55,676 | 35,804
Primary Care [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 4,402 | 12,977 | 26,477 | 24,277
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 7,514 | 0 | 17,099 | 0
Primary Care [Member] | Eliquis alliance revenues and direct sales [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,464 | 1,346 | 5,001 | 4,470
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 1,607 | 1,447 | 4,601 | 3,971
Primary Care [Member] | Premarin family [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 110 | 148 | 327 | 420
Primary Care [Member] | Nimenrix [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 79 | 51 | 221 | 145
Primary Care [Member] | BMP2 [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 58 | 71 | 201 | 186
Primary Care [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 67 | 47 | 177 | 161
Primary Care [Member] | Toviaz [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 30 | 56 | 130 | 174
Primary Care [Member] | Trumenba [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 60 | 52 | 108 | 102
Primary Care [Member] | Chantix / Champix [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 4 | 7 | 8 | 409
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 451 | 479 | 1,326 | 1,490
Specialty Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,404 | 3,749 | 10,267 | 11,205
Specialty Care [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 602 | 501 | 1,766 | 1,454
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 502 | 610 | 1,304 | 1,734
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 230 | 283 | 767 | 888
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 178 | 181 | 598 | 515
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 131 | 172 | 403 | 485
Specialty Care [Member] | Ig Portfolio Products [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [5] | 124 | 99 | 356 | 311
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 99 | 104 | 325 | 328
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 98 | 107 | 302 | 306
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 90 | 95 | 261 | 284
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 71 | 66 | 250 | 198
Specialty Care [Member] | Medrol [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 79 | 109 | 235 | 320
Specialty Care [Member] | Fragmin [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 60 | 74 | 202 | 223
Specialty Care [Member] | Somavert [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 70 | 70 | 202 | 203
Specialty Care [Member] | ReFacto AF/Xyntha [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 58 | 69 | 188 | 235
Specialty Care [Member] | Vfend [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 51 | 51 | 171 | 204
Specialty Care [Member] | All other Anti-infectives [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 374 | 455 | 1,123 | 1,384
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 586 | 702 | 1,816 | 2,134
Oncology [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 3,070 | 3,085 | 9,124 | 9,091
Oncology [Member] | Ibrance [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,283 | 1,381 | 3,841 | 4,039
Oncology [Member] | Xtandi alliance revenues [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 320 | 309 | 878 | 879
Oncology [Member] | Inlyta [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 252 | 256 | 760 | 742
Oncology [Member] | Zirabev [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 146 | 96 | 432 | 311
Oncology [Member] | Bosulif [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 141 | 136 | 425 | 395
Oncology [Member] | Xalkori [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 118 | 116 | 362 | 371
Oncology [Member] | Ruxience [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 120 | 124 | 357 | 343
Oncology [Member] | Retacrit [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 87 | 110 | 308 | 322
Oncology [Member] | Sutent [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 75 | 142 | 287 | 537
Oncology [Member] | Lorbrena [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 99 | 67 | 247 | 193
Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 73 | 54 | 198 | 122
Oncology [Member] | Aromasin [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 66 | 56 | 187 | 159
Oncology [Member] | Besponsa [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 55 | 50 | 164 | 145
Oncology [Member] | Braftovi [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [6] | 58 | 47 | 156 | 136
Oncology [Member] | Trazimera [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 51 | 45 | 149 | 131
Oncology [Member] | Mektovi [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 45 | 41 | 129 | 112
Oncology [Member] | All other Oncology [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | $ 80 | $ 53 | $ 243 | $ 155
[1] | On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the former Hospital therapeutic area (see footnote (b) below). Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations. See Note 1A.
[2] | See Note 1A for information about our recent organizational changes. PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($7 million and $108 million for the third quarter and the first nine months of 2022, respectively, and $187 million and $274 million for the third quarter and the first nine months of 2021, respectively), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. Prior to the fourth quarter of 2021, PC1 was managed within our former Hospital product portfolio.
[3] | Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization.
[4] | Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).
[5] | Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig.
[6] | Erbitux® is a registered trademark of ImClone LLC.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PaxlovidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PremarinFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NimenrixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BMP2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TrumenbaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ChantixChampixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherPrimaryCareProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VyndaqelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InflectraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IgPortfolioProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BeneFIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZaviceftaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MedrolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FragminMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SomavertMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VfendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherSpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZirabevMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalkoriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_RuxienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_RetacritMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LorbrenaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BavencioAllianceRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AromasinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BesponsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BraftoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TrazimeraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MektoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |